“We are not looking for a cheap deal, we are looking for the right deal.” This is the mindset for Ipsen’s chief business officer, Philippe Lopes-Fernandes. He is leading the charge for Ipsen’s deal-making strategy, as the company seeks growth in a disrupted pharma market.
Ipsen, a pureplay pharma company, does not have an internal discovery machine. It uses an external development model. “We are different from other players,” said Lopes-Fernandes.